Shannon C. Trotter, DO, is a dermatologist and podcast host from Springfield, Ohio.

Dermatologists are often the first to detect advanced cutaneous squamous cell carcinoma and should stay involved after oncology referral.

Pembrolizumab, cemiplimab, and cosibelimab are approved immune checkpoint inhibitors for locally advanced and metastatic disease.

Proposed Medicare cuts could delay skin cancer diagnosis and treatment for older patients.

Dermatologists should stay engaged in caring for patients with locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC), even after referral to oncology, according to Shannon C. Trotter, DO, FAOCD, a board-certified dermatologist with Dermatologists of the Central States in Ohio.

, Trotter discussed immunotherapy options for advanced cSCC, proposed Medicare cuts, and the future of artificial intelligence (AI) in skin cancer care.

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC

On October 10, at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, Trotter and Todd E. Schlesinger, MD, copresented “Seminar-In-Depth: Deep Dive on Cutaneous Squamous Cell Carcinoma and the Latest in Immunotherapy.”¹

Trotter noted about 95% of cSCC cases are treatable, while roughly 5% become more difficult to manage. She highlighted 3 immune checkpoint inhibitors approved for locally advanced and metastatic cSCC: pembrolizumab (Keytruda), cemiplimab (Libtayo), and cosibelimab (Unloxcyt). Research into intralesional use, particularly with cemiplimab, may also create a role for dermatologists in the office.

“They may seem far off to the dermatologist, but we are really the quarterbacks in skin cancer. We might be the first one to actually detect it, whether that is on the skin or even palpating for a lymph node. So we really need to be involved in our patients’ care, even if they are sent over to oncology as well,” Trotter said.

Trotter also described proposed Medicare cuts as a patient access issue. Older adults, who are disproportionately affected by skin cancer, could face delays in diagnosis and treatment. Survival in melanoma approaches 100% with early detection, she noted, and she encouraged the dermatology community to sign a petition opposing the cuts.

Looking ahead, Trotter pointed to augmented intelligence, which combines AI with clinician judgment, as a key opportunity in both melanoma and nonmelanoma skin cancer. New diagnostic tools may enable earlier detection. Gene expression profiling, alone or combined with AI, can provide prognostic information and may eventually guide therapeutic decisions.

Editor's Note: This summary has been edited for grammar and clarity using artificial intelligence tools. Trotter had no financial disclosures of note.

Schlesinger TE, Trotter SC. Seminar-in-depth: deep dive on cutaneous squamous cell carcinoma and the latest in immunotherapy. Presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

Videos

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Credit: Rosalind Franklin University Chicago Medical School

Chovatiya said the priority in moderate to severe atopic dermatitis is moving patients who are uncontrolled on topicals onto a systemic therapy, often a biologic.

He said choosing among dupilumab, tralokinumab and lebrikizumab means weighing differences in trial design, patient populations, outcomes and safety.

Remibrutinib is now the first FDA-approved treatment for symptomatic dermographism, which gives clinicians an on-label option for an inducible urticaria they have largely treated off-label.

 now select from several biologics targeting IL-13 signaling, including dupilumab, tralokinumab, and lebrikizumab. With limited head-to-head data, differences in study design, patient populations, outcome measures, and safety reporting complicate both indirect comparisons and shared decision-making with patients.

The pipeline continues to widen beyond injectable monotherapy. Investigational strategies include daily oral small molecules aiming for biologic-level efficacy, bispecific and trispecific antibodies designed to raise the efficacy ceiling, and targets outside conventional atopic dermatitis pathways.

Advances in urticaria have arrived on a parallel track. On October 7, 2026, the 

 approved remibrutinib (Rhapsido; Novartis), an oral Bruton's tyrosine kinase inhibitor, for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.¹ The agency first approved remibrutinib for chronic spontaneous urticaria on September 30, 2025.²

Novartis describes symptomatic dermographism as the most prevalent form of chronic inducible urticaria.¹ In the phase 3 RemIND trial, 29.3% (17/58) of patients receiving remibrutinib 25 mg twice daily achieved a complete Total Fric Score response at week 12 compared with 14.0% (8/57) receiving placebo (

 = .0229).³ Responses emerged as early as week 2.¹

The label expansion gives dermatologists an on-label option for a population historically managed with off-label therapy. Raj Chovatiya, MD, PhD, is an associate professor at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, Illinois. Chovatiya spoke with the 

2026 Fall Clinical Dermatology Conference

 in Las Vegas about biologic selection, emerging therapeutic strategies, the remibrutinib approval, and his research on overlapping dermatologic and gastrointestinal comorbidities:

: What are the key takeaways from your session on biologic decision-making for moderate to severe atopic dermatitis?

At this year's Fall Clinical meeting, I had the opportunity to talk all about our biologic landscape for atopic dermatitis and, in particular, how we make treatment decisions based on the data available to us. If there are a couple of points I really want people to take away, number one: There really are no wrong answers as long as you're able to get your systemic therapy-ready patient on a systemic therapy. For many patients, that's going to be a biologic. There are a lot of different reasons why you might choose a biologic therapy, but as long as you can help your patient get past that hump of remaining uncontrolled on topicals, you're doing a good thing.

My second point is a very important one: Understand the data as it relates to our current biologic therapies. We have an embarrassment of riches, more so than we've ever had in the world of atopic dermatitis, and on paper, it can sometimes be very difficult to make choices, especially when talking to your patient about treatments like dupilumab, tralokinumab, and lebrikizumab. In the world of medications that can block IL-13, it's important to, one, understand how the data compare to one another, if not directly, then indirectly, particularly in the way of differences in trial designs, patient populations, different types of outcomes of interest, and safety, and two, really try to find a way to easily translate that into the real world to ultimately equip you and your patient to make the best treatment choice possible.

: Coming off EADV 2026, which updates in atopic dermatitis or other inflammatory diseases are you watching this year and next?

In the world of atopic dermatitis, there's a lot of therapeutic innovation continuing to happen. It really hasn't slowed down in the last 10 years, and at EADV 2026 this year in Vienna, we had a number of late-breaking and cutting-edge talks that were really designed to give us a lot of hope for what's happening in the future of this disease state. I'll focus on a few ideas that I think are really important to where we're at in atopic dermatitis.

One is the idea of: Can we make for a more convenient patient experience when it comes to thinking about treatment? We have a whole host of oral molecules that are trying to target well-validated targets to ultimately allow our patients to achieve biologic-like efficacy in the form of a daily oral medication.

Another big theme has been trying to raise the efficacy ceiling. If we combine targets that we do know with ones that we don't know and put them all together in a single biologic therapy, might we be able to safely and effectively increase treatment response in our patients? This is the theme of multispecific antibodies, i.e., bispecific and trispecific antibodies, which we've paid very close attention to over the last few years.

Finally, theme number 3: What about targets that are well off the beaten path, that don't necessarily have anything to do with atopic dermatitis at the forefront of our minds, but may in fact be a way that we can safely and effectively treat even more patients? This is the other big theme that continues to loom as we start to think outside the box and look at various treatment targets that may not necessarily be household names but potentially offer us a chance to really change the course of disease.

: Remibrutinib was just approved for symptomatic dermographism. What might this approval mean for clinicians and their patients?

 This is some exciting news breaking in 2026 before we make our way deep into the fall. Remibrutinib, a Bruton's tyrosine kinase, or BTK, inhibitor, has really been game-changing for us in the world of chronic spontaneous urticaria. Now, our latest update comes from the world of inducible forms of urticaria, essentially the whole host of other chronic urticarial diseases where, based on outside influences and clear triggers, urticaria can happen.

Symptomatic dermatographism is the newest indication for us. Whenever you've spent time in the doctor's office tracing with a little bit of pressure on somebody's back and noticing that, indeed, urticaria can form, that's what we're talking about. For many folks in the world of dermatology treatment, there's been a lot of off-label use of therapies, and this is a really exciting movement for us to have an on-label indication for what can be an extremely uncomfortable and chronic issue for a lot of our patients dealing with chronic urticaria. I'd say this is probably one of several more indications to come in the life of remibrutinib, and ultimately, a really exciting piece of news that I'm happy I can use to help my patients.

: What research are you currently working on that you would like to highlight for colleagues?

In the world of research, there are oftentimes a lot of things I'm working on with various members of my group, fellows, and students, and things that really strike our interest in the world of dermatology. I could spend another hour catching you up on everything I'm interested in, but one area of research that has really caught a lot of our attention is trying to better understand comorbid burden as it relates to diseases where we oftentimes expect there to be some degree of overlap, as well as some where there isn't quite so much.

One of the things that's been very interesting to me, as the husband of a very successful and smart gastroenterologist, is understanding the overlap between dermatologic disease and gastroenterologic disease. Jointly, we've been working together to better understand some of the overlapping comorbid burden as it relates to both hepatic disease and gastrointestinal disease compared with some of the disease states we think about all the time, both the more common associations, when we think about psoriasis and hidradenitis suppurativa, as well as the less common associations, like vitiligo. More results to follow, so stay tuned.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Chovatiya previously reported serving as an adviser, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Novartis. Novartis Rhapsido (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). Published October 7, 2026. Accessed October 11, 2026. 

https://www.novartis.com/us-en/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu

Novartis. Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral targeted BTKi treatment for chronic spontaneous urticaria (CSU). Published September 30, 2025. Accessed October 11, 2026. 

https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu

Johnson V. Remibrutinib receives FDA approval for symptomatic dermographism. HCPLive. Published October 7, 2026. Accessed October 11, 2026. 

https://www.hcplive.com/view/remibrutinib-receives-fda-approval-symptomatic-dermographism

Articles

Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Christopher Maulion, MD | Image Credit: Yale School of Medicine

GLP-1 or dual GLP-1 and GIP receptor agonists substantially reduce pulmonary artery (PA) pressure in patients with 

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

 in Phoenix, Arizona, by Christopher Maulion, MD, assistant professor of medicine at Yale University School of Medicine.

“Limited data exist on their direct hemodynamic effects in patients with obesity and HF,” Maulion and colleagues wrote. “This study evaluated the effects of GLP-1 and dual GLP-1 and GIP on hemodynamic parameters measured by the CardioMEMs HF system, loop diuretic requirements, and HF hospitalizations.”

The CardioMEMs device, developed by Abbott and approved by the US Food and Drug Administration in 2014, is a wireless sensor implanted inside a branch of the pulmonary artery via an outpatient catheterization procedure. The device allows for real-time remote monitoring of PA pressure, which serves as an early indicator of HF due to its position as an indicator of fluid buildup. The device allows clinicians to intervene prior to the onset of acute cardiac decompensation.

Maulion and colleagues conducted a multicenter retrospective analysis using the Yale Joint Data Analytics Team (JDAT) database, identifying patients with HF who had been implanted with the CardioMEMs system and who had received either semaglutide or tirzepatide for ≥6 months during the study period. The team recorded baseline demographics, PA pressures, weight, use of loop diuretics, and biomarkers were measured at baseline and 3 and 6 months after treatment initiation. Additionally, significant cardiac events, including HF hospitalizations and urgent care visits, were recorded 1 year before and 1 year after initiation.

A total of 506 patients were implanted with the CardioMEMs system – of these, 60 patients were included in the present study for analysis. 48 of these patients initiated treatment with semaglutide, while 12 were treated with tirzepatide. The mean age among these patients was 63.7 +/- 14.5 years, and 65% of patients were male. The mean baseline weight was 116 +/- 25 kg. Baseline PA systolic pressure was 46 +/- 13 mmHg.

Substantial reductions in systolic PA pressure were recorded at 3 months (-2.75 +/- 7.37 mmHg; 

 = .02) and 6 months (-3.74 +/- 8.47 mmHg; 

 = .01) following treatment initiation. Maulion and colleagues also reported a decrease in PA mean pressure of -2.67 +/- 5.55 mmHg (

 = .007) and PA diastolic pressure of -1.7 +/- 3.95 mmHg (

 = .02) at 6 months. Weight also decreased by -2.77 +/- 4.1 kg (-2.3%) at 3 months and -5.19 +/- 7.23 kg (-4.4%) at 6 months.

Maulion and colleagues noted that loop diuretic use decreased from 85% at baseline to 67% at 6 months, with no significant change in furosemide equivalent dosing (

 = .26). Similarly, HF hospitalizations decreased from 1.2 +/- 1.42 to 0.3 +/- 0.62 per year (

 <.001). The team found a modest correlation between changes in weight and PA pressure during the study period (r = .18; 

Ultimately, the team concluded that initiation of either GLP-1 agonists or dual GLP-1/GIP agonists led to substantial reductions in PA pressures among patients with HF. Additionally, the weight reductions shown in this analysis were lower compared to prior cardiovascular outcome trials.

“Additional research is warranted to elucidate the mechanisms underlying these treatments in HF and obesity,” Maulion and colleagues wrote.

Opayemi I, Tong G, Zeng Y, et al. Retrospective Analysis of GLP-1 Receptor Agonist Use and Hemodynamic Trends in Heart Failure Patients With Cardiomems HF System. Abstract presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, Phoenix, AZ. October 9-12, 2026.

Tolu-Akinnawo O, Akhtar N, Zalavadia N, Guglin M. CardioMEMS Heart Failure System: An Up-to-Date Review. Cureus. 2025;17(1):e77816. Published 2025 Jan 22. 

A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations

Theodore Abraham, MD | Image Credit: UCSF Health

A recent analysis of the SEQUOIA-HCM trial has demonstrated aficamten’s association with mild reductions in right ventricular free wall longitudinal strain (RVFWLS) and substantial reductions in right ventricular systolic pressure (RVSP).

 in Phoenix, Arizona, by Theodore Abraham, MD, the Meyer Friedman Distinguished Professor of Medicine and clinical chief of cardiology at the University of California at San Francisco. The study’s established purpose was to evaluate the effects of aficamten on the right ventricle, given the lack of evidence surrounding this interaction.

“Aficamten, a next-in-class cardiac myosin inhibitor, improved left ventricular outflow tract (LVOT) gradient, exercise capacity, quality of life, and echocardiographic measures of left-sided cardiac structure and function in patients with 

obstructive hypertrophic cardiomyopathy (oHCM)

,” Abraham and colleagues wrote. “The effects of aficamten on right ventricular (RV) function and RV-pulmonary artery (PA) coupling remain incompletely characterized.”

SEQUOIA-HCM was a phase 3, randomized, placebo-controlled, double-blind, multicenter trial evaluating aficamten’s safety and efficacy in patients with oHCM. Patients were eligible for inclusion if they had a body mass index (BMI) <35 kg/m2, were diagnosed with HCM via left ventricular (LV) hypertrophy or end-diastolic LV wall thickness and had a resting LVOT gradient ≥30 mmHg and post-Valsalva LVOT gradient ≥50 mmHg, among other criteria.

Patients were randomly assigned in a 1:1 ratio to receive either aficamten or placebo – randomization was stratified based on the use of beta-blockers and cardiopulmonary exercise testing modality. The primary endpoint was change from baseline in peak oxygen uptake (pVO2) at week 24, while secondary endpoints included change from baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Symptoms Score (KCCQ-CSS) at weeks 12 and 24, as well as the proportion of patients with ≥1 class improvement in New York Heart Association (NYHA) functional class from baseline at weeks 12 and 24.

A total of 282 patients underwent randomization, with 142 assigned to the aficamten group and 140 to the placebo group. At baseline, mean LV ejection fraction was 74.8%, and mean resting LVOT gradient was 55.1 mmHg. By week 24, the mean change in pVO2 was 1.8 ml/kg/min in the aficamten arm (95% CI, 1.2 to 2.3) and 0 ml/kg/min in the placebo group (95% CI, -0.5 to 0.5). Additionally, aficamten treatment improved all secondary endpoints compared with placebo.

In the present analysis, Abraham and colleagues measured RVFWLS and RV 4-chamber longitudinal strain (RV4CLS) at baseline and week 24 via speckle-tracking echocardiography. RVSP was estimated with tricuspid regurgitation velocity, and RV-PA coupling was determined through the RVFWLS/RVSP ratio. Additionally, the team used multivariable linear regression to evaluate the effects of aficamten treatment and associations between changes in clinical parameters and changes in RV strain.

Of the 282 patients included in the study, baseline RV strain measurements were feasible in 230 patients, split evenly between the treatment and placebo arms. Mean age among these patients was 59 +/- 13 years with a mean resting LVOT gradient 56 +/- 30 mmHg. At baseline, mean absolute RVFWLS was 24.5 +/- 5.1%, and mean absolute RV4CLS was 18.4 +/- 4%. Baseline resting RVSP was estimated successfully in 138 patients, with a mean value of 25.9 +/- 6.2 mmHg.

By week 24, aficamten was associated with modest reductions in RVFWLS compared to placebo (-1.2%; 95% CI, -2.3 to -0.1%; 

 = .029) but remained within normal range. RV4CLS was unchanged after treatment (-0.5%; 95% CI, -1.3 to 0.3%; 

 = .25). Additionally, Abraham and colleagues found that aficamten substantially reduced RVSP (-4.3 mmHg; 95% CI, -7.1 to -1.5 mmHg; 

 = .003), which ultimately translated to no significant change in the RVFWLS-RVSP ratio. These changes were not associated with changes in pVO2, KCCQ scores, or NYHA functional class.

“In patients with oHCM, aficamten was associated with a mild reduction in RVFWLS that remained within the normal range, alongside a significant reduction in RVSP, leading to preserved RV-PA coupling,” Abraham and colleagues wrote. “Changes in RV strain were not associated with other clinical measures and provide reassurance regarding RV performance with aficamten treatment.”

Hamatani Y, Manafi A, Abraham T, et al. Association of Aficamten Treatment with Right Ventricular Function and Pulmonary Coupling in Obstructive Hypertrophic Cardiomyopathy: Results from the SEQUOIA-HCM Trial. Abstract presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, Phoenix, AZ. October 9-12, 2026.

Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine. 2024;390(20):1849-1861. 

Cytokinetics. Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM). ClinicalTrials.gov Identifier: NCT05186818. Updated March 3, 2026. Accessed October 11, 2026. 

https://clinicaltrials.gov/study/NCT05186818?term=NCT05186818&rank=1

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

Cardiomyopathy

Aficamten Improves Right Ventricular Strain, Systolic Pressure in oHCM

Ulrich Jorde, MD, is a professor in the department of medicine at Albert Einstein College of Medicine and Montefiore Einstein.

Following successful results from the DORAYA-HF feasibility study, the Doraya catheter is primed to enter a pivotal trial in hospitalized patients with 

Pivotal Trial of Doraya Catheter in HF Planned After Success in Feasibility Trial

 in Phoenix, Arizona, by Ulrich Jorde, MD, a professor in the department of medicine at Albert Einstein College of Medicine and Montefiore Einstein.

“Hopefully, Doraya will enable clinically meaningful decongestion, accelerate the process, reduce lengths of stay, and then discharge the patient in a fully decongested state,” Jorde told 

 in an exclusive interview. “All of that, of course, is right now only in registries, in open-label studies with no control group. But we’re getting ready to refine the exact parameters for the trial, which I anticipate will start in early 2027.”

Patients hospitalized for heart failure typically exhibit volume overload, with roughly 1 in 3 dealing with inadequate diuretic response. Doraya is an implantable catheter deployed percutaneously in the inferior vena cava below the renal veins. The distal frame opening is adjusted to partially obstruct the venous flow, reducing cardiac preload and congestion. This, in turn, triggers a series of hemodynamic effects that begin with unloading the renal venous system, taking pressure off the renal veins and kidneys.

DORAYA-HF was conducted across 14 locations and enrolled patients with a primary diagnosis of acute decompensated heart failure (ADHF), NT-proBNP ≥1000 pg/m, evidence of fluid overload, and insufficient response to intravenous diuretic therapy. Patients with systolic blood pressure <90 mmHg, acute myocardial infarction or acute coronary syndrome within 14 days, or complex congenital heart disease, among other criteria, were excluded from the trial.

Patients were treated with either diuretics alone or the Doraya catheter with diuretics. The device was placed transfemorally in the IVC for ≤12 hours. The primary outcome was the change in urine output over 24 hours, while the primary safety endpoint was the incidence of device- or procedure-related serious adverse events within 30 days.

The study ultimately enrolled 16 patients between 2022 and 2024, who were treated at 6 US sites. Mean age was 68 +/- 12 years, and 63% of patients were male. Mean left ventricular ejection fraction was 39 +/- 16%, and eGFR was 41 +/- 18 mL/min/1.73m2. The Doraya catheter was successfully implanted in all 16 patients; the investigators recorded no device-related adverse events and 1 procedure-related adverse event.

Of the patients given the device, 3 required hospital readmission due to worsening heart failure out to 60 days. Urine output increased from 80 mL/hour at baseline to 224.1 mL/hour during device dwell (

 <.01) and remained elevated at 24 hours, where it reached 153.2 mL/hour (

 <.01). Central venous pressure and pulmonary capillary wedge pressure both decreased substantially, while urine sodium, dyspnea, jugular venous pressure, and edema grade all improved (

Ultimately, the investigators determined that the Doraya device demonstrated safety and efficacy in this patient population, with no device-related adverse events. The improvements noted in urine output, hemodynamics, and congestion symptoms supported ongoing research, which is expected to culminate with the pivotal trial planned for early 2027.

“The pivotal trial is obviously a big step for patients, but also for the company to see where this is going in the spectrum of device therapy for cardiorenal syndrome,” Jorde said. “There are multiple devices at this moment, but I feel that this is probably the one that is the least invasive, possibly the safest, and we’ll see whether it’s also very efficacious.”

Editors’ Note: Jorde reports a relevant disclosure with Abbott.

Jorde U. Trial Tinder Trial #2: DORAYA-HF Pivotal Trial. Presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, Phoenix, AZ. October 9-12, 2026.

Klein L, Chung E, Cheng R, et al. Results of the early feasibility study of renal venous afterload modulation with the Doraya device in acute decompensated heart failure patients. Journal of Cardiac Failure. 2026;32(1):202. 

Zymliński R, Dierckx R, Biegus J, Vanderheyden M, Bartunek J, Ponikowski P. Novel IVC Doraya Catheter Provides Congestion Relief in Patients With Acute Heart Failure. JACC Basic Transl Sci. 2022;7(3):326-327. Published 2022 Apr 4. 

Revamp Medical Inc. DORAYA-HF Early Feasibility Study. ClinicalTrials.gov Identifier: NCT05206422. Updated August 13, 2026. Accessed October 10, 2026. 

https://clinicaltrials.gov/study/NCT05206422?term=NCT05206422&rank=1

Ulrich Jorde, MD, discusses the Doraya device’s positive results in the DORAYA-HF feasibility study and Revamp Medical’s plans for a pivotal trial in early 2027.

In this interview, Iltefat Hamzavi, MD, explains why early advanced therapy in hidradenitis suppurativa matters beyond pivotal trial primary endpoints.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Why Early Advanced Therapy Matters in Hidradenitis Suppurativa

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes

Iltefat Hamzavi, MD, outlines how symptom questionnaires, comorbidity screening, wound care, and procedures shape hidradenitis suppurativa care.

Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Fall Clinical 2026 First Half Recap: Psoriasis, Atopic Dermatitis, and More

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Cardiovascular Hospitalization Associated With Increased Mortality Risk in ATTR-CM

New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

ICONIC-LEAD: Icotrokinra Sustains Psoriasis Skin Clearance at 2 Years

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD

Iltefat Hamzavi, MD, explains how topical and oral JAK inhibitors fit into vitiligo care and which patients are the best candidates for each approach.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Latest News

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations

Aficamten Improves Right Ventricular Strain, Systolic Pressure in oHCM

Pivotal Trial of Doraya Catheter in HF Planned After Success in Feasibility Trial